Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Keysight Technologies Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Keysight Technologies Inc trades at $344 (market cap $57.32B). The key difference: Keysight Technologies Inc is far larger — about 6.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Keysight Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BIO | KEYS | |
|---|---|---|
Market Cap | $9.39B | $57.32B |
Sector | Health | Technology |
52-Week High | $354.54 | $373.34 |
52-Week Low | $241.71 | $158.51 |
Enterprise Value | $9.14B | $57.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Keysight Technologies (KEYS) trades at $340.97, up 1.19% today, near its 52-week high. The stock shows strong momentum with bullish moving averages and consistent earnings beats, including Q1 2026 EPS of $2.87 versus $2.32 expected. Revenue for 2025 reached $5.38B with a net income margin of 17.31%. Recent news highlights product innovations like the APS-ONE-400 cybersecurity platform and collaborations with Intel and the European Space Agency, reinforcing growth prospects in 5G and defense markets.
Outlook remains positive with a consensus price target of $396.56, implying 16% upside, supported by 81% analyst buy ratings. Risks include elevated valuation multiples (P/E 54.91) and high RSI levels suggesting overbought conditions. Investors should monitor execution on 2026 revenue guidance of $6.1B and manage exposure to tech sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
